GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (OTCPK:MYCOF) » Definitions » EV-to-Revenue

Mydecine Innovations Group (Mydecine Innovations Group) EV-to-Revenue : (As of May. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mydecine Innovations Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Mydecine Innovations Group's enterprise value is $4.78 Mil. Mydecine Innovations Group's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Mydecine Innovations Group's EV-to-Revenue for today is .

The historical rank and industry rank for Mydecine Innovations Group's EV-to-Revenue or its related term are showing as below:

During the past 10 years, the highest EV-to-Revenue of Mydecine Innovations Group was 33917.50. The lowest was -38525.88. And the median was 397.31.

MYCOF's EV-to-Revenue is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.41
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), Mydecine Innovations Group's stock price is $0.01124. Mydecine Innovations Group's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Therefore, Mydecine Innovations Group's PS Ratio for today is .


Mydecine Innovations Group EV-to-Revenue Historical Data

The historical data trend for Mydecine Innovations Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group EV-to-Revenue Chart

Mydecine Innovations Group Annual Data
Trend Dec13 Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.70 36.18 25,372.32 5,648.17 -

Mydecine Innovations Group Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,704.40 - - - -

Competitive Comparison of Mydecine Innovations Group's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mydecine Innovations Group's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's EV-to-Revenue falls into.



Mydecine Innovations Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Mydecine Innovations Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4.779/0
=

Mydecine Innovations Group's current Enterprise Value is $4.78 Mil.
Mydecine Innovations Group's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mydecine Innovations Group  (OTCPK:MYCOF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Mydecine Innovations Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.01124/0
=

Mydecine Innovations Group's share price for today is $0.01124.
Mydecine Innovations Group's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mydecine Innovations Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group (Mydecine Innovations Group) Business Description

Traded in Other Exchanges
Address
789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.